Inactivation of the Hutchinson strain of hepatitis non-A, non-B virus in intravenous immunoglobulin by beta-propiolactone

J Med Virol. 1988 Nov;26(3):227-32. doi: 10.1002/jmv.1890260302.


beta-propiolactone (beta-PL) treatment has been evaluated for its ability to inactivate 10(3.5) chimpanzee infectious doses (CID50) of the Hutchinson strain of hepatitis non-A, non-B virus (HNANBV). Two chimpanzees were inoculated with a beta-PL-treated immunoglobulin solution to which this dose of the titrated virus had been added prior to beta-PL treatment. beta-PL treatment was performed in accordance with the production procedure used for a licensed intravenous immunoglobulin preparation. Neither animal developed hepatitis. When subsequently challenged with the same spiked immunoglobulin solution that had not been beta-PL treated, both animals developed clear-cut hepatitis non-A, non-B. The results of this experiment demonstrate that beta-PL treatment is effective for the inactivation of hepatitis non-A, non-B virus in intravenous immunoglobulin.

MeSH terms

  • Animals
  • Antiviral Agents
  • Drug Contamination
  • Drug Evaluation, Preclinical
  • Female
  • Hepatitis C / prevention & control*
  • Hepatitis C / transmission
  • Hepatitis Viruses / drug effects*
  • Hepatitis, Viral, Human / prevention & control*
  • Immunoglobulins / administration & dosage
  • Immunoglobulins / adverse effects*
  • Injections, Intravenous
  • Lactones / pharmacology*
  • Pan troglodytes
  • Propiolactone / pharmacology*


  • Antiviral Agents
  • Immunoglobulins
  • Lactones
  • Propiolactone